Erotic electrostimulation

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Retrieved on: 
Thursday, May 13, 2021
Medical devices, Health, Other Health, Other Science, Science, Biotechnology, Human sexuality, Academic disciplines, Sexology, Intel X99, Pulse, Erotic electrostimulation

b'Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation\xe2\x84\xa2 (NPS\xe2\x84\xa2) technology, today announced the podium presentation of four clinical studies of NPS technology at the American Society for Laser Medicine and Surgery (ASLMS) Virtual Annual Meeting taking place on May 15-16, 2021.

Key Points: 
  • b'Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation\xe2\x84\xa2 (NPS\xe2\x84\xa2) technology, today announced the podium presentation of four clinical studies of NPS technology at the American Society for Laser Medicine and Surgery (ASLMS) Virtual Annual Meeting taking place on May 15-16, 2021.
  • Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy.
  • The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes.
  • These statements are not historical facts but rather are based on Pulse Biosciences\xe2\x80\x99 current expectations, estimates, and projections regarding Pulse Biosciences\xe2\x80\x99 business, operations and other similar or related factors.

StimaWELL North America Inc. Enters the US Market With Its State-of-the-art, Back-pain Relief, E Stim Therapy + Tens Device Called the StimaWELL 120MTRS; a Game-changer for Neck + Back Pain Recovery.

Retrieved on: 
Thursday, April 22, 2021
Technology, Health, Hardware, Medical devices, Branches of biology, Nervous system, Acute pain, Symptoms and signs, Pain, Pain management, Palliative care, Erotic electrostimulation, Back pain, Reinforcement

Since 80% of North American\xe2\x80\x99s experience neck + back pain1, the e-stim (EMS) market is experiencing exponential growth.

Key Points: 
  • Since 80% of North American\xe2\x80\x99s experience neck + back pain1, the e-stim (EMS) market is experiencing exponential growth.
  • StimaWELL North America Inc. is excited to deliver its superior quality, German manufactured products across the US.
  • This means that you can target any muscle in the back for reinforcement or pain relief.
  • I truly feel this is a game-changer for neck + pain relief and will help individuals and athletes recover faster and take their game to the next level.\xe2\x80\x9d\n'

Pulse Biosciences Announces FDA Clearance for the CellFX® System

Retrieved on: 
Wednesday, February 3, 2021
Biotechnology, General Health, FDA, Medical devices, Health, Human sexuality, Sexology, Erotic electrostimulation, Masturbation, Sexual fetishism, LinkedIn Pulse, Sexuality

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced U.S. Food and Drug Administration (FDA) clearance of the CellFX System for dermatologic procedures requiring ablation and resurfacing of the skin.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced U.S. Food and Drug Administration (FDA) clearance of the CellFX System for dermatologic procedures requiring ablation and resurfacing of the skin.
  • FDA clearance for the CellFX System is a tremendous achievement for Pulse Biosciences.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
  • These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors.

Pulse Biosciences Grants Equity Incentive Awards To New Employees

Retrieved on: 
Tuesday, December 15, 2020
Biotechnology, Pharmaceutical, Health, Medical devices, Human sexuality, Sexology, Erotic electrostimulation, Masturbation, Sexual fetishism, Pulse, Sexuality

Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse Biosciences or the Company) a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 40,250 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on December 15, 2020.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse Biosciences or the Company) a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 40,250 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on December 15, 2020.
  • The options have an exercise price of $18.40 per share, which is equal to the closing price of Pulse Biosciences common stock on December 15, 2020.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

Retrieved on: 
Wednesday, October 7, 2020
Health, Surgery, Clinical trials, Medical devices, Branches of biology, Human sexuality, Biology, Bioelectromagnetics, Physiology, Radiobiology, Pulse, Erotic electrostimulation

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients.

Key Points: 
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients.
  • Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.
  • Caution: Pulse Biosciences CellFX System and Nano-Pulse Stimulation technology are for investigational use only.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

Retrieved on: 
Thursday, October 1, 2020
Medical devices, FDA, Health, Other Health, Pharmaceutical, Biotechnology, Human sexuality, Branches of biology, Biology, Investigational device exemption, Pharmaceutical industry, IDE, Food and Drug Administration, Sebaceous gland, Erotic electrostimulation, Hyperplasia, Insulin-degrading enzyme, Sebaceous Hyperplasia, Pulse Biosciences®

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX System.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX System.
  • Following IDE approval, several patients have been enrolled, with the first patient procedure completed on September 28, 2020.
  • We are pleased to have received FDA IDE approval and to have begun this important SH comparative study slightly ahead of the fourth quarter start we had previously communicated.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Pulse Biosciences Announces Receipt of MDSAP Certification

Retrieved on: 
Tuesday, September 29, 2020
Health, Medical devices, Technology, Nanotechnology, Pharmaceutical, Hardware, Biotechnology, Human sexuality, Articles, Magazines, Erotic electrostimulation, Masturbation, Sexual fetishism, Bioelectromagnetics, Pulse

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced the receipt of Medical Device Single Audit Program certification.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced the receipt of Medical Device Single Audit Program certification.
  • Certification through these programs validate our ongoing commitment to maintaining the highest quality assurance standards within the medical device industry as required by regulatory authorities across the world, said Darrin Uecker, President and CEO of Pulse Biosciences.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
  • These statements are not historical facts but rather are based on Pulse Biosciences current expectations, estimates, and projections regarding Pulse Biosciences business, operations and other similar or related factors.

Pulse Biosciences Grants Equity Incentive Awards To New Employees

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, Pharmaceutical, Health, Medical devices, Human sexuality, Sexuality, Erotic electrostimulation, Masturbation, Sexual fetishism, Pulse

Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse Biosciences or the Company) a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 77,250 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 15, 2020.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse Biosciences or the Company) a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the Compensation Committee of the Companys Board of Directors granted non-qualified stock options covering an aggregate of 77,250 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 15, 2020.
  • The options have an exercise price of $11.67 per share, which is equal to the closing price of Pulse Biosciences common stock on September 15, 2020.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Nano-Pulse Stimulation™ Technology Produces Favorable Results in Several Clinical Studies Presented at the 2020 Laser Medicine and Surgery Virtual Annual Conference

Retrieved on: 
Wednesday, July 1, 2020
Medical devices, Health, Branches of biology, Human sexuality, Academic disciplines, Biophysics, Bioelectromagnetics, Electromagnetism, Physiology, Radiobiology, Pulse, Erotic electrostimulation

Pulse Biosciences did not direct content or influence the planning or implementation of the ASLMS Online Learning Center.

Key Points: 
  • Pulse Biosciences did not direct content or influence the planning or implementation of the ASLMS Online Learning Center.
  • The spontaneous opinions expressed by speakers and participants during these activities belong to those individuals.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients.
  • Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.

Global Transcutaneous Electrical Nerve Stimulation Market (2019 to 2025) - Industry Analysis, Trends, Market Size, and Forecast

Retrieved on: 
Thursday, June 18, 2020
Neurotechnology, Branches of biology, Medicine, Neuroscience, Electrotherapy, Pain management, Medical equipment, Transcutaneous electrical nerve stimulation, Neuromodulation, Erotic electrostimulation

The report on the global transcutaneous electrical nerve stimulation market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Key Points: 
  • The report on the global transcutaneous electrical nerve stimulation market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report predicts the global transcutaneous electrical nerve stimulation market to grow with a healthy CAGR over the forecast period from 2019-2025.
  • The report on transcutaneous electrical nerve stimulation market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global transcutaneous electrical nerve stimulation market over the period of 2017 to 2025.
  • Complete coverage of all the segments in the transcutaneous electrical nerve stimulation market to analyze the trends, developments in the global market and forecast of market size up to 2025.